Acadia Pharmaceuticals Inc. ACAD, -3.04% said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug Administration on Friday approved Daybue, the first therapy to treat Rett syndrome, a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April. Acadia’s stock is up 23.2% so far this year, while the broader S&P 500 SPX, +0.16% has gained about 1.0%.
This article was originally published by Marketwatch.com. Read the original article here.
